Lixte Biotechnology Holdings, Inc. closed fiscal year 2025 with $12.7M in total assets, $1.8M in total liabilities and $9.7M in shareholder equity. Total assets rose 1011.6% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Lixte Biotechnology Holdings, Inc. has filed alongside them.
Ticker history: LIXT became NMAD (Nomad Power Solutions, Inc.) on .
Annual figures, oldest first. Point at a bar to read its period.
LIXT Balance Sheet by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.7M+1011.6% | $1.1M-73.4% | $4.3M-22.5% | $5.6M+9.2% | $5.1M-2.6% | $5.2M+95.7% | $2.7M-38.4% | $4.3M+217.0% | $1.4M+215.7% | $433K-27.5% | $598K+10.9% | $539K-3.4% | $558K-68.2% | $1.8M+307.9% | $430K |
| Total Liabilities | $1.8M+456.8% | $318K+1.4% | $314K-20.7% | $396K+30.6% | $303K+39.9% | $217K-9.0% | $238K+12.8% | $211K-43.5% | $373K+70.6% | $219K-23.5% | $286K+4.5% | $273K-15.0% | $322K+23.2% | $261K-25.5% | $351K |
| Total Equity | $9.7M+1068.3% | $827K-79.3% | $4.0M-22.7% | $5.2M+7.8% | $4.8M-4.4% | $5.0M+105.9% | $2.4M-41.0% | $4.1M+314.6% | $995K+363.3% | $215K-31.2% | $312K+17.5% | $266K+12.5% | $236K-84.2% | $1.5M+1787.9% | $79K |
LIXT Balance Sheet by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.9M+617.5% | $12.7M+1011.6% | $5.4M+220.4% | $1.2M-55.4% | $1.5M-57.8% | $1.1M-73.4% | $1.7M-67.6% | $2.7M-13.8% | $3.6M-17.1% | $4.3M-22.5% | $5.2M-23.2% | $3.1M-61.4% |
| Total Liabilities | $1.7M+375.0% | $1.8M+456.8% | $521K+58.5% | $537K+27.4% | $355K-23.3% | $318K+1.4% | $329K+5.5% | $421K+4.7% | $463K+85.1% | $314K-20.7% | $312K-23.7% | $403K-24.3% |
| Total Equity | $7.9M+585.4% | $9.7M+1068.3% | $4.9M+259.4% | $651K-71.0% | $1.2M-62.9% | $827K-79.3% | $1.4M-72.2% | $2.2M-16.6% | $3.1M-23.4% | $4.0M-22.7% | $4.9M-23.2% | $2.7M-64.1% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Lixte Biotechnology Holdings, Inc. financials
Frequently Asked Questions
Lixte Biotechnology Holdings, Inc. closed fiscal year 2025 with $12.7M in total assets, $1.8M in total liabilities and $9.7M in shareholder equity.
Lixte Biotechnology Holdings, Inc. (LIXT) total assets rose by 1011.6% year over year, from $1.1M to $12.7M in fiscal year 2025.
Across the 15 fiscal years this page covers, Lixte Biotechnology Holdings, Inc. (LIXT) total assets went from $430K in fiscal year 2011 to $12.7M in fiscal year 2025.
Lixte Biotechnology Holdings, Inc. (LIXT) reported $10.9M in total assets in Q1 2026. This represents an increase of 617.5% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Lixte Biotechnology Holdings, Inc. (LIXT) reported on that line in every period on record.